RPA1 and acute myocardial infarction: Reteplase (recombinant plasminogen activator, rPA) is a thrombolytic agent approved by the Food and Drug Administration (http://en.wikipedia.org/wiki/Food_and_Drug_Administration) in 1996 for the management of acute myocardial infarction (AMI) in adults, in the reduction of the incidence of congestive heart failure, and for reduction of mortality associated with AMI.